DOET(2,5-Dimethoxy-4-Ethylamphetamine), a New Psychotropic Drug
Archives of General Psychiatry 1971 DOI: 10.1001/archpsyc.1971.01750070052006 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Controlled trial Peer reviewed |
|---|---|
| Population | Normal male subjects |
| Intervention | DOET |
| Dose | 0.75 to 4 mg |
| Topics | LSD Mescaline Psilocybin |
| Keywords | Psychotomimetic Hallucinogen Euphoriant Amphetamine Pharmacology Psychotropic drug |
| Citations | 30 |
| Key findings | DOET produced mild euphoria and enhanced self-awareness without hallucinogenic or psychotomimetic effects at doses up to 4 mg. |
Abstract
DOET (2,5-dimethoxy-4-ethylamphetamine) is a new psychotropic agent which chemically resembles mescaline and amphetamine. It is essentially the ethyl homologue of DOM (2,5-dimethoxy-4-methylamphetamine), a psychotomimetic drug widely used by hippie populations and designated "STP." DOET was administered to normal male subjects in doses ranging from 0.75 to 4 mg and contrasted with effects of a water placebo. In all cases DOET produced subjective effects including a mild euphoria, a feeling of enhanced self-awareness, and a tendency to feel "anxious" at higher doses. Although there was some increase in subjective effects at higher doses, this was not marked. No hallucinogenic or psychotomimetic effects were observed at any dose. Thus, over a five-fold range of pharmacologically active dosage, the "enhanced awareness" produced by DOET was not associated with psychotomimetic or hallucinogenic actions. PSYCHEDELIC drugs embrace a large number of agents of widely different chemical classes but which produce notably similar profound subjective effects.1Nuances of subjective effects which may vary among drugs2have not been well quantified. Shulgin3.4has synthesized a large number of methoxylated amphetamines related to mescaline and amphetamine. One of these, DOM (2, 5-dimethoxy-4-methylamphetamine) (Fig 1), informally designated "STP," was psychotomimetic and hallucinogenic in doses larger than 5 mg, and was about 50 to 100
Comparable studies
Other non-randomized and open-label trials on mescaline, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| The paradoxical psychological effects of lysergic acid diethylamide (LSD) Healthy volunteers | 2016 | Within-subjects controlled trial | n = 20 |
| Psychological Effects and Metabolism of N,N-diethyltryptamine in Man Chronic schizophrenic patients and normal volunteers | 1966 | Controlled trial | n = 20 |
| Pharmacokinetics, Pharmacodynamics, and Urinary Recovery of Oral Mescaline Hydrochloride in Healthy Participants. Healthy human participants | 2025 | Clinical trial (phase I) | n = 49 |
Citations in the library
Cited by 12
- Stereospecific binding ofd-lysergic acid diethylamide (LSD) to brain membranes: Relationship to serotonin receptors Brain Research September 1, 1975
- Stereospecific Actions of DOET (2,5-Dimethoxy-4-Ethylamphetamine) in Man Archives of General Psychiatry July 1, 1974
- The effects of 2,5-dimethoxy-4-methylamphetamine (DOM), 2,5-dimethoxy-4-ethylamphetamine (DOET), d-amphetamine, and cocaine in rats trained with mescaline as a discriminative stimulus Psychopharmacology 1975
- 1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents - A Review. ACS Pharmacology & Translational Science June 14, 2024
- Constructing the ecstasy of MDMA from its component mental organs: Proposing the primer/probe method. Medical Hypotheses February 1, 2016
and 7 more in the library